Esanex's Series A Round

Esanex raised a round of funding on December 12, 2012.

Esanex is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors. SNX-5422, created from a novel chemical scaffold that is unique in the Hsp90 field, has …

Articles about Esanex's Series A Round: